Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Intangibles (2020 - 2025)

Historic Intangibles for 10x Genomics (TXG) over the last 6 years, with Q4 2025 value amounting to $62.3 million.

  • 10x Genomics' Intangibles rose 29773.47% to $62.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.3 million, marking a year-over-year increase of 29773.47%. This contributed to the annual value of $62.3 million for FY2025, which is 29773.47% up from last year.
  • 10x Genomics' Intangibles amounted to $62.3 million in Q4 2025, which was up 29773.47% from $64.8 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Intangibles registered a high of $64.8 million during Q3 2025, and its lowest value of $14.7 million during Q2 2025.
  • For the 5-year period, 10x Genomics' Intangibles averaged around $25.1 million, with its median value being $22.3 million (2023).
  • As far as peak fluctuations go, 10x Genomics' Intangibles tumbled by 2971.5% in 2024, and later surged by 30100.94% in 2025.
  • Quarter analysis of 5 years shows 10x Genomics' Intangibles stood at $25.4 million in 2021, then fell by 10.0% to $22.9 million in 2022, then decreased by 27.31% to $16.6 million in 2023, then fell by 5.69% to $15.7 million in 2024, then soared by 297.73% to $62.3 million in 2025.
  • Its Intangibles stands at $62.3 million for Q4 2025, versus $64.8 million for Q3 2025 and $14.7 million for Q2 2025.